Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, placebo controlled, randomized study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics following single, escalating subcutaneous doses of PF-04603629 in type 2 diabetic adult subjects

Trial Profile

Phase 1, placebo controlled, randomized study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics following single, escalating subcutaneous doses of PF-04603629 in type 2 diabetic adult subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2011

At a glance

  • Drugs PF 4603629 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top